drugset
drugset / Trial / NCT05277376

Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial

NCT05277376 ↗

Phase 3 Completed 162 enrolled dsm-firmenich Switzerland AG
RandomizedFactorialOpen-labelBasic science

Summary

An open-label, randomized, 3-arm study in 162 healthy adult subjects with the following primary objective: To assess the systemic absorption and pharmacokinetics of BEMT from 3 market image sunscreen formulations under maximal-use conditions.

Timeline

Start
2022-03-15
Primary completion
2022-10-28
Completion
2022-10-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bemotrizinol Unknown 0.12 mg Topical

Indications

No indication recorded.